Magnasense Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Marco Wititteveen

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	1.1yrs
CEO ownership	n/a
Management average tenure	1.1yrs
Board average tenure	2.5yrs

Recent management updates

Recent updates

CEO

Marco Wititteveen

1.1yrs

Tenure

Mr. Marco Wititteveen serves as Chief Executive Officer of Magnasense AB (formerly known as AegirBio AB (publ)) since June 15, 2023. He has previously had multiple different roles in Med Tech and diagnosti...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Bradley Messmer	Chief Scientific Officer & Member of the Board	no data	SEK 1.28m	1.39% SEK 16.1k
Marco Wititteveen	Chief Executive Officer	1.1yrs	no data	no data
Niklas Andersson	Chief Financial Officer	1.5yrs	no data	no data
Vasiliki Fragkou	Chief Operating Officer	less than a year	no data	no data

1.1yrs

Average Tenure

Experienced Management: 52Q's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Bradley Messmer	Chief Scientific Officer & Member of the Board	4.4yrs	SEK 1.28m	1.39% SEK 16.1k
Seppo Makinen	Independent Member of the Board	4.4yrs	SEK 168.00k	no data
William Vickery	Independent Director	2.5yrs	no data	no data
Iain L. Chapple	Member of Scientific Advisory Board	less than a year	no data	no data
Sofia Bertling	Independent Director	2.5yrs	no data	no data
Fredrik Haglund	Independent Member of the Board	4.2yrs	SEK 48.00k	0.52% SEK 6.0k
Adam Cheifetz	Scientific Advisory Board	less than a year	no data	no data
Melissa Grant	Member of Scientific Advisory Board	no data	no data	no data

2.5yrs

Average Tenure

54yo

Average Age

Experienced Board: 52Q's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.

Magnasense Management

Management criteria checks 0/4

Key information

Recent management updates

AegirBio AB Appoints Melissa Grant to its Scientific Advisory Board

AegirBio AB (publ), Annual General Meeting, Jun 28, 2024

AegirBio AB (publ), Annual General Meeting, Jun 28, 2024

AegirBio AB (publ) Announces Intention of Anders Ingvarsson to Resign as Board Member and Chairman

AegirBio AB (Publ) Announces the Appointment of Iain L. C. Chapple to the Scientific Advisory Board

AegirBio AB (publ) Appoints Adam S. Cheifetz as Scientific Advisory Board

Recent updates

AegirBio AB Appoints Melissa Grant to its Scientific Advisory Board

AegirBio AB (publ), Annual General Meeting, Jun 28, 2024

AegirBio AB (publ), Annual General Meeting, Jun 28, 2024

First quarter 2024 earnings released: kr0.16 loss per share (vs kr0.64 loss in 1Q 2023)

AegirBio AB (publ) Announces Intention of Anders Ingvarsson to Resign as Board Member and Chairman

Full year 2023 earnings released: kr2.38 loss per share (vs kr18.90 loss in FY 2022)

AegirBio AB (Publ) Announces the Appointment of Iain L. C. Chapple to the Scientific Advisory Board

AegirBio AB (publ) Appoints Adam S. Cheifetz as Scientific Advisory Board

Aegirbio AB Receives Phase 1 Award from the National Institutes of Health (Nih) Rapid Acceleration of Diagnostics (Radx®) Tech Program for an Accessibility Project for Multiplex Testing

AegirBio Announces Management Changes

Aegirbio AB (Publ) Announces CEO Changes

High number of new directors

AegirBio AB (publ) announced that it expects to receive SEK 55 million in funding from Atlas Special Opportunities LLC

High number of new and inexperienced directors

High number of new and inexperienced directors

AegirBio Receives Approval from the Notified Body to Prolong the Shelf Life of Its Covid-19 Antigen Test

AegirBio Announces First Clinical Saliva TDM Study in US

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

AegirBio AB (publ) Receives Intention to Grant from the European Patent Office

Aegirbio Announces the Addition of Brandon Steele to Their Senior Management Team as Chief Commercial Officer

AegirBio AB (publ) (OM:AEGIR) agreed to acquire LifeAssays AB (publ) (NGM:LIFE B)

New 90-day high: €2.34

AegirBio AB (publ) Announces That the Direct Aid of Approximately SEK 4.3 Million or €419,500 Granted to Aegirbio AB’s Eurostar application

New 90-day high: €2.31

Aegirbio Commences FDA Fast Track Process with COVID-19 Test

Aegirbio Announces Convincing Results for Aegirbio's Coronavirus Test in Italian-Swedish Study

Aegirbio AB Signs A Research & Development Agreement with MediaPharma

AegirBio AB (publ) (OM:AEGIR) acquired Viraspec AB for SEK 10 million.

CEO

Tenure

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age